Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway

Leukemia

Volumn 26, Issue 12, 2012, Pages 2546-2549

  Xu, S ^a,b,c   Evans, H ^d   Buckle, C ^d   De Veirman, K ^b,c   Hu, J ^c   Xu, D ^c   Menu, E ^c   De Becker, A ^b   Vande Broek, I ^c   Leleu, X ^e   Camp, B V ^c   Croucher, P ^d   Vanderkerken, K ^c   Van Riet, I ^b,c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; TRANSCRIPTION FACTOR RUNX2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; BONE DEVELOPMENT; BONE DISEASE; BONE LESION; BONE MARROW; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; LETTER; MESENCHYMAL STEM CELL; MINERALIZATION; MONOCLONAL IMMUNOGLOBULINEMIA; MOUSE; MULTIPLE MYELOMA; NONHUMAN; NOTCH SIGNALING PATHWAY; OSSIFICATION; OSTEOBLAST; OSTEOGENIC DIFFERENTIATION; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; BONE MARROW; CELL DIFFERENTIATION; COLONY-FORMING UNITS ASSAY; FETUS; HUMANS; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; MULTIPLE MYELOMA; OSTEOGENESIS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84871207138     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.126     Document Type: Letter

References (15)

1. Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne MN, Crinquette A et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 2007; 21: 158-163.
2. Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury Cappellesso S et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 2007; 21: 1079-1088.
3. Garderet L, Mazurier C, Chapel A, Ernou I, Boutin L, Holy X et al. Mesenchymal stem cell abnormalities in patients with multiple myeloma. Leuk Lymphoma 2007; 48: 2032-2041.
4. Garayoa M, Garcia JL, Santamaria C, Garcia-Gomez A, Blanco JF, Pandiella A et al. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia 2009; 23: 1515-1527.
5. Vanderkerken K, De Raeve H, Goes E, Van Meirvenne S, Radl J, Van Riet I et al. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer 1997; 76: 451-460.
6. Meirelles Lda S, Nardi NB. Murine marrow-derived mesenchymal stem cell: isolation, in vitro expansion, and characterization. Br J Haematol 2003; 123: 702-711.
7. Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Donofrio G, Bonomini S et al. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res 2007; 67: 7665-7674.
8. Standal T, Abildgaard N, Fagerli UM, Stordal B, Hjertner O, Borset M et al. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 2007; 109: 3024-3030.
9. Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005; 106: 3160-3165.
10. Vallet S, Pozzi S, Patel K, Vaghela N, Fulciniti MT, Veiby P et al. A novel role for CCL3 (MIP-1a) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Leukemia 2011; 25: 1174-1181.
11. Zanotti S, Smerdel-Ramoya A, Stadmeyer L, Durant D, Radtke F, Canalis E. Notch inhibits osteoblast differentiation and causes osteopenia. Endocrinology 2008; 149: 3890-3899.
12. Hilton MJ, Tu X, Wu X, Bai S, Zhao H, Kobayashi T et al. Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat Med 2008; 14: 306-314.
13. Zanotti S, Smerdel-Ramoya A, Canalis E. HES1 (hairy and enhancer of split 1) is a determinant of bone mass. J Biol Chem 2011; 286: 2648-2657.
14. Engin F, Lee B. NOTCHing the bone: insights into multi-functionality. Bone 2010; 46: 274-280.
15. He W, Luistro L, Carvajal D, Smith M, Nevins T, Yin X et al. High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the g-secretase inhibitor, RO4929097. Mol Oncol 2011; 5: 292-301.